Immunologic pathomechanism of Hodgkin's lymphoma

Experimental Hematology

Volumn 41, Issue 12, 2013, Pages 995-1004

  Jona, Adam ^a   Szodoray, Peter ^b   Illés, Arpad ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ALEMTUZUMAB; BLEOMYCIN; BRENTUXIMAB VEDOTIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GALIXIMAB; GEMCITABINE; LENALIDOMIDE; LESTAURTINIB; OSTEOCLAST DIFFERENTIATION FACTOR; PANOBINOSTAT; PENTOSTATIN; RITUXIMAB; ROMIDEPSIN; TENASCIN; VINBLASTINE; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CUTANEOUS T CELL LYMPHOMA; EPSTEIN BARR VIRUS; GENE MUTATION; GENETIC DISORDER; HODGKIN AND REED STERNBERG CELL; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PARACRINE SIGNALING; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REED STERNBERG CELL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT;

B-LYMPHOCYTES; GENES, IMMUNOGLOBULIN; HODGKIN DISEASE; HUMANS;

EID: 84888878737     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.09.014     Document Type: Review

References (104)

1. Hodgkin On some morbid appearances of the absorbent glands and spleen. Med Chir Trans 1832, 17:68-114.
2. Reed D. On the pathological changes in Hodgkin's disease with special reference to its relation to tuberculosis. John Hopkins Hosp Rep 1902, 10:133-193.
3. Sternberg C. Über eine eigenartige unter dem Bilde der Pseudoleukämie verlaufende Tuberkolose des lymphatischen Apparates. Zeitschrift für Heilkunde 1898, 19:21-90.
4. Kuppers R., Rajewsky K., Zhao M., et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A 1994, 91:10962-10966.
5. Bonadonna G., Zucali R., Monfardini S., De Lena M., Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975, 36:252-259.
6. Duggan D.B., Petroni G.R., Johnson J.L., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003, 21:607-614.
7. Kanzler H., Kuppers R., Hansmann M.L., Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996, 184:1495-1505.
8. Marafioti T., Hummel M., Foss H.D., et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000, 95:1443-1450.
9. Schwering I., Brauninger A., Klein U., et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003, 101:1505-1512.
10. Hansmann ML, Weiss LM, Stein H, Harris NL, Jaffe ES. Hodgkin's disease. 1999:169-180.
11. Bargou R.C., Leng C., Krappmann D., et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996, 87:4340-4347.
12. Mathas S., Lietz A., Anagnostopoulos I., et al. c-FLIP Mediates Resistance of Hodgkin/Reed-Sternberg Cells to Death Receptor-induced Apoptosis. J Exp Med 2004, 199:1041-1052.
13. Kashkar H., Haefs C., Shin H., et al. XIAP-mediated Caspase Inhibition in Hodgkin's Lymphoma-derived B Cells. J Exp Med 2003, 198:341-347.
14. Re D., Hofmann A., Wolf J., Diehl V., Staratschek-Jox A. Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95. Exp Hematol 2000, 28:31-35.
15. Re D., Thomas R.K., Behringer K., Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005, 105:4553-4560.
16. Falzetti D., Crescenzi B., Matteuci C., et al. Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease. Haematologica 1999, 84:298-305.
17. Martín-Subero J., Gesk S., Harder L., et al. Recurrent involvement of the REL and BCL11Aloci in classical Hodgkin lymphoma. Blood 2002, 99:1474-1477.
18. Joos S., Küpper M., Ohl S., et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 2000, 60:549-552.
19. Kupper M., Joos S., von Bonin F., et al. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol 2001, 112:768-775.
20. Thomas R., Re D., Wolf J., Diehl V. Part I: Hodgkin's lymphoma-molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 2004, 5:11-18.
21. Chang K.C., Khen N.T., Jones D., Su I.J. Epstein-Barr virus is associated with all histological subtypes of Hodgkin lymphoma in Vietnamese children with special emphasis on the entity of lymphocyte predominance subtype. Hum Pathol 2005, 36:747-755.
22. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, eds. Philadelphia: Lippincott-Raven; 2001:2575-2627.
23. Poppema S. Immunobiology and pathophysiology of hodgkin lymphomas. Hematology 2005, 2005:231-238.
24. Yamamoto R., Nishikori M., Kitawaki T., et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008, 111:3220-3224.
25. Farrell K., Jarrett R.F. The molecular pathogenesis of Hodgkin lymphoma. Histopathology 2011, 58:15-25.
26. Skinnider B.F., Mak T.W. The role of cytokines in classical Hodgkin lymphoma. Blood 2002, 99:4283-4297.
27. Uchihara J., Krensky A., Matsuda T., et al. Transactivation of the CCL5/RANTES gene by Epstein-Barr virus latent membrane protein 1. Int J Cancer 2005, 114:747-755.
28. Kiss E., Kovacs L., Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev 2010, 9:195-199.
29. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009, 9:15-27.
30. Barth T.F.E., Martin-Subero J.I., Joos S., et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood 2003, 101:3681-3686.
31. Jungnickel B., Staratschek-Jox A., Brauninger A., et al. Clonal deleterious mutations in the I{kappa}b{alpha} gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000, 191:395-402.
32. Emmerich F., Theurich S., Hummel M., et al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol 2003, 201:413-420.
33. Schmitz R., Hansmann M.-L., Bohle V., et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009, 206:981-989.
34. Kato M., Sanada M., Kato I., et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009, 459:712-716.
35. Baus D., Pfitzner E. Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. Int J Cancer 2006, 118:1404-1413.
36. Kube D., Holtick U., Vockerodt M., et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001, 98:762-770.
37. Skinnider B.F., Elia A.J., Gascoyne R.D., et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2002, 99:618-626.
38. Scheeren F.A., Diehl S.A., Smit L.A., et al. IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood 2008, 111:4706-4715.
39. Ihle J.N. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001, 13:211-217.
40. Holtick U., Vockerodt M., Pinkert D., et al. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia 2005, 19:936-944.
41. Hinz M., Lemke P., Anagnostopoulos I., et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002, 196:605-617.
42. Skinnider B.F., Elia A.J., Gascoyne R.D. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2001, 97:250-255.
43. Kapp U., Yeh W.C., Patterson B. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999, 189:1939-1946.
44. Mottok A., Renne C., Willenbrock K., Hansmann M.-L., Brauninger A. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 2007, 110:3387-3390.
45. Scheeren F.A., Diehl S.A., Smit L.A., et al. IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood 2008, 111:4706-4715.
46. Mathas S., Hinz M., Anagnostopoulos I., et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. Embo J 2002, 21:4104-4113.
47. Watanabe M., Ogawa Y., Ito K., et al. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells. Am J Pathol 2003, 163:633-641.
48. Jundt F., Anagnostopoulos I., Forster R., Mathas S., Stein H., Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002, 99:3398-3403.
49. Schwarzer R., Dorken B., Jundt F. Notch is an essential upstream regulator of NF-kappaB and is relevant for survival of Hodgkin and Reed-Sternberg cells. Leukemia 2012, 26:806-813.
50. Dutton A., Reynolds G.M., Dawson C.W., Young L.S., Murray P.G. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005, 205:498-506.
51. Zheng B., Fiumara P., Li Y.V., et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30CD40, and RANK that regulates cell proliferation and survival. Blood 2003, 102:1019-1027.
52. Campo E., Swerdlow S.H., Harris N.L., Pileri S., Stein H., Jaffe E.S. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011, 117:5019-5032.
53. Samoszuk M., Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 1990, 75:13-16.
54. Aldinucci D., Gloghini A., Pinto A., De Filippi R., Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010, 221:248-263.
55. Tan T.T., Coussens L.M. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007, 19:209-216.
56. Maggio E., van den Berg A., Diepstra A., Kluiver J., Visser L., Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002, 13:52-56.
57. Cattaruzza L., Gloghini A., Olivo K., et al. Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. Int J Cancer 2009, 125:1092-1101.
58. Touati M., Delage-Corre M., Monteil J., et al. CD68+ tumor-associated macrophages predict unfavorable treatment outcomes in classic Hodgkin's lymphoma in correlation with early FDG-PET assessment results. Blood 2011, 118:1558.
59. Casulo C., Arcila M., Teruya-Feldstein J., Maragulia J., Moskowitz C.H. Tumor-associated macrophages are predictive of survival in relapsed and refractory Hodgkin lymphoma. Blood 2011, 118:2630.
60. Steidl C., Lee T., Shah S., et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010, 362:875-885.
61. Casasnovas R.-O., Mounier N., Brice P., et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007, 25:1732-1740.
62. Weihrauch M.R., Manzke O., Beyer M., et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res 2005, 65:5516-5519.
63. Hsi E. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Leuk Lymphoma 2008, 49:1668-1680.
64. Thompson C., Maurer M., Cerhan J., et al. Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. Am J Hematol 2011, 86:998-1000.
65. Gruss H.J., Herrmann F., Gattei V., Gloghini A., Pinto A., Carbone A. CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Leuk Lymphoma 1997, 24:393-422.
66. Younes A. CD30-targeted antibody therapy. Curr Opin Oncol 2011, 23:587-593.
67. Chiu A., Xu W., He B., et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 2007, 109:729-739.
68. Schreck S., Friebel D., Buettner M., et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 2009, 27:31-39.
69. Gandhi M.K., Moll G., Smith C., et al. Galectin-1 mediated suppression of Epstein-Barr virus specific T cell immunity in classic Hodgkin lymphoma. Blood 2007, 110:1326-1329.
70. Newcom S.R., Gu L. Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. J Clin Pathol 1995, 48:160-163.
71. Chemnitz J.M., Driesen J., Classen S., et al. Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: Implications in Hodgkin's lymphoma. Cancer Res 2006, 66:1114-1122.
72. Tanijiri T., Shimizu T., Uehira K., et al. Hodgkin's Reed-Sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. J Leukoc Biol 2007, 82:576-584.
73. Ma Y., Visser L., Blokzijl T., et al. The CD4+CD26- T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile. Lab Invest 2008, 88:482-490.
74. Terasawa T., Lau J., Bardet S., et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B cell lymphoma: a systematic review. J Clin Oncol 2009, 27:1906-1914.
75. Khandani A., Dunphy C., Meteesatien P., Dufault D., Ivanovic M., Shea T. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2009, 30:594-601.
76. Matsui T., Nakata N., Nagai S., et al. Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J Nucl Med 2009, 50:920-926.
77. Rodig S.J., Abramson J.S., Pinkus G.S., et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006, 12:7174-7179.
78. Peggs K., Sureda A., Qian W., et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007, 139:70-80.
79. Thomson K., Peggs K., Smith P., et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008, 41:765-770.
80. Oki Y., Younes A. Does rituximab have a place in treating classic hodgkin lymphoma?. Curr Hematol Malig Rep 2010, 5:135-139.
81. Younes A., Oki Y., McLaughlin P., et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 2012, 119:4123-4128.
82. Garnock-Jones K.P. Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. Drugs 2013, 73:371-381.
83. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. New Engl J Med 2010, 363:1812-1821.
84. Younes A., Gopal A.K., Smith S.E., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012, 30:2183-2189.
85. Forero-Torres A., Berryman R.B., Advani R.H., et al. Prolonged treatment with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). ASH Annu Meeting Abstracts 2011, 118:3711.
86. Illidge T., Bouabdallah R., Chen R.W., et al. Allogeneic transplant following brentuximab vedotin treatment in patients with relapsed or refractory CD30+ lymphomas. ASH Annu Meeting Abstracts 2011, 118:3091.
87. Chen R., Palmer J.M., Thomas S.H., et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012, 119:6379-6381.
88. Younes A., Connors J.M., Park S.I., Hunder N.N.H., Ansell S.M. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. ASH Annu Meeting Abstracts 2011, 118:955.
89. Forero-Torres A., Fanale M., Advani R., et al. Brentuximab vedotin in transplant-naive patients with relapsed or refractory Hodgkin lymphoma: Analysis of two phase I studies. Oncologist 2012, 17:1073-1080.
90. Brogdon J.L., Xu Y., Szabo S.J. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007, 109:1123-1130.
91. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007, 26:5420-5432.
92. Heider U., Kaiser M., Sterz J. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 2006, 76:42-50.
93. Wang S., Yan-Neale Y., Cai R., Alimov I., D C Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824. Cell Cycle 2006, 5:1662-1668.
94. Buglio D., Georgakis G.V., Hanabuchi S., et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008, 112:1424-1433.
95. Younes A., Sureda A., Ben-Yehuda D., et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012, 30:2197-2203.
96. Chanan-Khan A.A., Cheson B.D. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008, 26:1544-1552.
97. Derenzini E., Lemoine M., Buglio D., et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J 2011, 1:e46.
98. Diaz T., Navarro A., Ferrer G., et al. Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. PLoS One 2011, 6:e18856.
99. Vooijs W., Otten H., van Vliet M., et al. B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease. Br J Cancer 1997, 76:1163-1169.
100. Sauer S., Erba P.A., Petrini M., et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009, 113:2265-2274.
101. Schliemann C., Wiedmer A., Pedretti M., Szczepanowski M., Klapper W., Neri D. Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 2009, 33:1718-1722.
102. Braiteh F., Ng C., Kurzrock R. Refractory Hodgkin lymphoma responds to pentostatin (2'-deoxycoformycin). Leuk Lymphoma 2006, 47:373-375.
103. Aldinucci D., Poletto D., Lorenzon D., et al. CD26 expression correlates with a reduced sensitivity to 2'-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas. Clin Cancer Res 2004, 10:508-520.
104. Oki Y., Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma 2008, 49:883-889.